Abstract
We describe a 5-year-old girl showed recovery of vincristine induced cranial polyneuropathy with pyridoxine and pyridostigmine treatment. A 5-year-old girl was diagnosed preB cell Acute Lymphoblastic Leukemia (ALL). She received chemotherapy according to the previously described modified St. Jude total therapy studies XIII. Five days after the fourth dose of vincristine, she presented with bilateral ptosis. Neurological examination revealed bilateral ptosis, and complete external opthalmoplegia with normal pupillary and corneal reflexes. She received 3.8 mg cumulative dose of vincristin before development of ptosis. A neuroprotective and neuroregenerative treatment attempt with pyridoxine and pyridostigmine was initiated. The bilateral ptosis markedly improved after 7 days of pyridoxine and pyridostigmine treatment and completely resolved after two weeks. The both agents were given for 3 weeks and were well tolerated without any side effects. During the follow up period we did not observe residue or recurrence of the ptosis.
References
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy.J Neurol 2002; 249: 9–17.
Chauvenet AR, Shashi V, Selsky C, Morgan E, Kurtzberg J, Bell B Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.J Pediatr Hematol Oncol 2003; 25: 316–320.
Moudgil SS, Riggs JE. Fulminant peripheral neuropathy with severe quadriparesis associated with vincristine therapy.Ann Pharmacother 2000; 34: 1136–1138.
Legha SS. Vincristine neurotoxicity. Pathophysiology and management.Med Toxicol 1986; 1: 421–427.
Yetgin S, Tuncer MA, Cetin Met al. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.Leukemia 2003; 17: 328–333.
Chan JD. Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports.Pharmacotherapy 1998; 18: 1304–1307.
Neumann Y, Toren A, Rechavi Get al. Vincristine treatment triggering the expression of asymptomatic Charcot-Marie-Tooth disease.Med Pediatr Oncol 1996; 26: 280–283.
Jackson DV, Jr., Pope EK, McMahan RAet al. Clinical trial of pyridoxine to reduce vincristine neurotoxicity.J Neurooncol 1986; 4: 37–41.
Battle WM, Snape WJ, Jr. Alavi Aet al. Colonic dysfunction in Diabetes mellitusGastroenterology 1980; 79: 1217–1221.
Muller L, Kramm CM, Tenenbaum T, Wessalowski R, Gobel U. Treatment of vincristine-induced bilateral ptosis with pyridoxine and pyridostigmine.Pediatr Blood Cancer 2004; 42: 287–288.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bay, A., Yilmaz, C., Yilmaz, N. et al. Vincristine induced cranial polyneuropathy. Indian J Pediatr 73, 531–533 (2006). https://doi.org/10.1007/BF02759902
Issue Date:
DOI: https://doi.org/10.1007/BF02759902